...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

Lophius Biosciences Achieves First Clinical Proof of Principle for T-Track® TB for Detection of Active Tuberculosis and Receives Research Funding

| Print |
Thursday, 08 November 2012 08:45 (UTC + 1)

lophius_logo_neu

Regensburg, Germany, November 8, 2012 / B3C newswire / - Lophius Biosciences, a leader in the field of novel T cell based diagnostic test systems, reported today about its first successfully concluded clinical Proof of Principle study with respect to detection of active tuberculosis (TB) using its novel T-Track® TB test which is based on Lophius Biosciences proprietary Reverse T Cell Technology (RT Technology).

The clinical Proof of Principle was concluded in India with a cohort of 44 patients. Results demonstrate that the T-Track® TB test was able to detect active TB in in 10 of 12 non-treated patients. Besides its high sensitivity and specificity the T-Track® TB test also demonstrated a remarkably short turnaround time of 2 days which compares favorably to currently used classical detection methods. In summary, these results imply that the T-Track® TB test could represent an innovative and fast detection approach for this area of strong medical need.

For further test development Lophius Biosciences has been awarded research funding of 140K EUR under the scope of the ZIM-solo-program from the German government. This funding should help to broaden the scope of the T-Track® TB tests with respect to detection of latent TB and potential patient-monitoring of treated TB subjects. The company will present first results at Medica mid November 2012 in Düsseldorf.

„We are very pleased to have accomplished clinical Proof of Principle for our second proprietary technology platform. Our short-term goal is geared towards test optimization and further validation in a bigger patient cohort” said Dr. Michael Lutz, CEO of Lophius Biosciences.

 
About Lophius Biosciences
Lophius Biosciences GmbH develops and markets innovative T cell based testing systems for diagnostics and possible therapy control in the fields of transplantation, infection and autoimmune diseases.


Contact  
Lophius Biosciences GmbH
Josef-Engert-Str. 13
D-93053 Regensburg
Phone: +49 941 6309 1972
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.lophius.de